The latest price target for CVS Health (NYSE:CVS) was reported by Truist Securities on November 20, 2024. The analyst firm set a price target for $67.00 expecting CVS to rise to within 12 months (a possible 17.61% upside). 47 analyst firms have reported ratings in the last year.

The latest analyst rating for CVS Health (NYSE:CVS) was provided by Truist Securities, and CVS Health reiterated their buy rating.

The last upgrade for CVS Health Corp happened on November 18, 2024 when Wells Fargo raised their price target to $66. Wells Fargo previously had an equal-weight for CVS Health Corp.

The last downgrade for CVS Health Corp happened on May 7, 2024 when TD Cowen changed their price target from $99 to $59 for CVS Health Corp.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of CVS Health, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for CVS Health was filed on November 20, 2024 so you should expect the next rating to be made available sometime around November 20, 2025.

While ratings are subjective and will change, the latest CVS Health (CVS) rating was a reiterated with a price target of $76.00 to $67.00. The current price CVS Health (CVS) is trading at is $56.97, which is out of the analyst’s predicted range.